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Abstract
Introduction. Transcatheter arterial embolization (TAE) and chemoembolization (TACE) are increasingly used to treat
unresectable primary and metastatic liver tumors. The purpose of this study was to determine the objective response to TAE
and TACE in unresectable hepatic malignancies and to identify clinicopathologic predictors of response. Materials and
methods. Seventy-nine consecutive patients who underwent 119 TAE/TACE procedures between 1998 and 2006 were
reviewed. The change in maximal diameter of 121 evaluable lesions in 56 patients was calculated from pre and post-
procedure imaging. Response rates were determined using Response Evaluation Criteria in Solid Tumors (RECIST)
guidelines. The Kaplan-Meier method was used to compare survival in responders vs. non-responders and in primary vs.
metastatic histologies. Results. TAE and TACE resulted in a mean decrease in lesion size of 10.3%91.9% (pB0.001).
TACE (vs. TAE) and carcinoid tumors were associated with a greater response (pB0.05). Lesion response was not
predicted by pre-treatment size, vascularity, or histology. The RECIST partial response (PR) rate was 12.3% and all partial
responders were in the TACE group. Neuroendocrine tumors, and specifically carcinoid lesions, had a significantly greater
PR rate (pB0.05). Overall survival, however, was not associated with histology or radiologic response. Discussion. TAE and
TACE produce a significant objective treatment response by RECIST criteria. Response is greatest in neuroendocrine
tumors and is independent of vascularity and lesion size. TACE appears to be superior to TAE. Although an association of
response with improved survival was not demonstrated, large cohort studies are necessary to further define this relationship.
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Introduction
Transcatheter arterial embolization (TAE) and che-
moembolization (TACE) are increasingly used as
regional therapeutic modalites for the treatment of
unresectable hepatic malignancies [14]. Despite the
increasing application of these embolization techni-
ques, the indications for their use remain ill-defined.
In general, TAE and TACE have been used when
surgical resection and/or systemic therapy have failed
to produce an adequate response or when conven-
tional therapy has been known to be ineffective.
Applied in this manner, TAE and TACE appear to
have a specific role in the multimodal management of
patients with unresectable hepatic malignancies.
TAE and TACE have been used extensively world-
wide since their introduction in the early 1980s [510].
Yet, technical issues and questions regarding therapeu-
tic efficacy remain. For example, uniform criteria for
patient selection have not been established and ther-
apeutic efficacy for varying histologies is unclear.
Furthermore, it has not been determined if the addi-
tion of chemotherapy (i.e., TACE) provides a signifi-
cant benefit over bland embolization (i.e., TAE) alone
[1,2,11]. Moreover, when TACE is performed, the
choice of chemotherapeutic agent(s) is often arbitrary,
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since no single regimen has a clear therapeutic advan-
tage. Finally, there is no consensus regarding the
necessity or timing of repeat embolization. As a result,
treatment decisions are largely made according to
individual and institutional biases.
Because the procedural details for TAE and TACE
have not been firmly established, we conducted a
review of our own institutional experience with TAE
and TACE in a consecutive series of patients
with primary and metastatic hepatic malignancies.
The primary aim of our study was to determine the
efficacy of TAE and TACE in producing an objective
radiographic tumor response in this population of
patients. Additional objectives were to identify pre-
dictive factors for improved response with respect to
histology, tumor vascularity, and pre-treatment lesion
size and to examine the potential association of
radiographic response with overall survival. Given
the lack of methodologic uniformity, we also present
an algorithmic approach for the use of TAE and
TACE in hepatic malignancies.
Materials and methods
Sample population
Seventy-nine consecutive patients who underwent a
total of 119 transcatheter embolization procedures
between 1998 and 2006 were identified from the City
of Hope National Medical Center, Institutional Re-
view Board (IRB)-approved Liver Tumor Database.
All patients were selected for treatment by a multi-
disciplinary City of Hope Liver Tumor Group. The
universal indication for treatment in this patient
population was the presence of liver-dominant, un-
resectable primary hepatocellular carcinoma (HCC)
or unresectable metastatic hepatic disease refractory
to systemic chemotherapy. TACE was the preferred
treatment modality for both primary and metastatic
tumors. TAE was used selectively when the adminis-
tration of chemotherapy was thought to carry prohi-
bitive risk based on the judgment of the individual
treating physicians. For HCC, embolization proce-
dures were limited to patients who did not meet
criteria for liver transplantation. The primary contra-
indications to treatment were the presence of severe
underlying liver dysfunction (Child’s C cirrhosis) or
other medical comorbidities with prohibitively high
risk for treatment-related complications. Main portal
vein thrombosis was also considered a contraindica-
tion to treatment. In the setting of peripheral/peritu-
moral portal vein obstruction, treatment was
considered in the absence of severe liver dysfunction.
Embolization technique
Chemoembolization was performed via a percuta-
neous transarterial approach in an angiography suite.
After the administration of conscious sedation and
the infiltration of local anesthesia, access to the
common femoral artery was established via the Sel-
dinger technique. Initial diagnostic digital subtraction
mesenteric and hepatic arteriography was performed
to evaluate vascular anatomy and to rule out significant
arteriovenous shunting.
After diagnostic angiography, selective emboliza-
tion of the distal tumor vasculature was performed.
For chemoembolization, doxorubicin (50 mg), mito-
mycin (10 mg), and cisplatin (150 mg) were emulsi-
fied in 15 ml of ethiodol and injected into the distal
tumor vasculature. This cocktail of chemotherapeutic
agents was chosen based on previous evidence de-
monstrating significant biologic and morphologic
tumor response in HCC, with improved survival
compared to previously used regimens [12]. The
same combination of agents was used for all histolo-
gies when performing TACE. Administration of
chemotherapy/ethiodol was followed immediately by
particulate embolization with polyvinyl alcohol (PVA)
microspheres of progressively increasing size (300
700 microns) until stasis of arterial flow to the tumor
was achieved. For TAE, ethiodol contrast without
chemotherapy was injected initially, followed by the
administration of PVA microspheres as above. Treat-
ment was always restricted to a single lobe per session
for both TAE and TACE. With large bilobar lesions,
additional sessions were scheduled at intervals of
approximately one month to embolize the remainder
of the untreated tumor vasculature. Retreatment of
successfully embolized lesions was not routinely
performed.
Assessment of radiologic response
Radiologic response to treatment was assessed by
retrospective review of pre and post-procedure ima-
ging. Abdominal computed tomography (CT) ima-
ging with and without intravenous contrast and
magnetic resonance imaging (MRI) were selected for
response assessment. Pre-procedure studies up to six
months prior to the date of treatment were reviewed.
Post-procedure studies were examined only if per-
formed ]30 days after treatment to allow for the
development of radiographic changes in the treated
lesions. When more than one embolization was
performed for the same lesion within a short time
interval (B2 months), the combined procedures
were considered a single treatment, and radiologic
response was assessed after the final embolization.
Response was calculated for both individual lesions
and for the overall procedure. Two by two measure-
ments of the three largest treated lesions were
recorded. Procedural response was categorized into
complete response (CR), partial response (PR), stable
disease (SD), and progressive disease (PD) based on
the Response Evaluation Criteria in Solid Tumors
(RECIST) guidelines [13]. We used RECIST size
criteria to evaluate treatment response because the
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methods to evaluate tumor necrosis as a result of
embolization have not been established; and the use of
RECIST size criteria allowed uniformity in assessing
response.
The vascularity of each lesion was categorized as
either hypervascular or hypovascular based on the
degree of radio-opaque contrast enhancement on
arterial phase images. In the case of non-contrast
scans, the vascularity of the lesion was coded as
missing. All measurements were confirmed by a
radiologist experienced in the performance of trans-
catheter embolization and the assessment of oncologic
response.
Of the 119 procedures, six were performed for the
same lesion(s) within two months of a previous
embolization and were considered part of a single
treatment for the purpose of response assessment. Of
the remaining procedures, 10 had no available pre-
procedure imaging, 26 had no available post-proce-
dure imaging and four had post-procedure imaging
performed less than 30 days after treatment. After
excluding the above, radiologic response was assessed
for a total of 73 procedures in 56 patients, with a total
of 121 treated, evaluable lesions.
Data collection
The medical records of the study patients were
reviewed for demographic information, details of the
embolization procedure, and complications during
the post-procedure hospital stay. Renal failure was
defined clinically as either post-procedure anuria/
oliguria unresponsive to fluid administration, post-
procedure dialysis requirement, and/or a rise in post-
procedure BUN/creatinine levels. Hepatic failure was
defined clinically as increasing ascites and encephalo-
pathy or post-procedure elevation of total bilirubin
levels and/or prothrombin time. Procedural mortality
was defined as death due to any cause within 30 days
of treatment. The design and details of the study were
approved by City of Hope IRB.
Statistical analysis
With respect to individual lesion response, the out-
come measure of interest was the change in maximal
diameter of each lesion. The mean decrease in maximal
diameter for all treated lesions was calculated and the
significance of the change determined using the paired
student’s t-test. Lesion response was then stratified
according to vascularity (hyper vs. hypo), type of
procedure (TAE vs. TACE), histology, and initial
lesion size (dichotomized near the median value). Due
to the small number of individual histologies in
patients with metastatic disease to the liver, metastatic
histologies were combined to allow for statistical
comparison with HCC. Differences in lesion response
by subgroup were assessed using a one-way analysis-
of-variance (ANOVA). Differences in RECIST re-
sponse rates by procedure type and tumor histology
were determined using the likelihood-ratio chi-square
test. In order to account for possible selection bias
caused by the exclusion of early deaths, the proce-
dural analysis was repeated after recategorizing those
patients who had no post-procedure imaging and died
within six months of treatment as having PD.
Overall patient survival was determined using the
Kaplan-Meier method. For the purposes of survival
comparison, patients were categorized as ‘‘respon-
ders’’ if they had either a CR or PR following any of
their embolization procedures, or ‘‘non-responders’’
in the case of stable or progressive radiologic disease.
The difference in survival between responders and
non-responders was assessed using the log-rank test.
A p-value of B0.05 was considered significant. The
statistical analysis was performed using Statistical
Analysis System (SAS) software version 9.1.3 service
pack 3 (SAS Institute Inc., Cary, NC, USA, 2002
2003).
Results
Table I shows the characteristics of the sample popula-
tion. The mean age at the time of first treatment
was 62.7913.0 years. Fifty-six percent of patients
were male. The majority (71%) had a normal or
near normal Eastern Cooperative Oncology Group
Table I. Characteristics of sample population (ECOG, Eastern
Cooperative Oncology Group; HCC, hepatocellular carcinoma;
GIST, gastrointestinal stromal tumor).
Variable Total population (n79)
Age (years, mean / SD) 62.7913.0
Gender
Male 44 (55.7%)
Female 35 (44.3%)
Race
Caucasian/Hispanic 57 (72.2%)
Asian 16 (20.3)
African-American 6 (7.5%)
ECOG status1
0 38 (48.1%)
1 26 (32.9%)
2 7 (8.9%)
3 6 (7.6%)
4 2 (2.5%)
Primary diagnosis
HCC 45 (57%)
Metastatic2 34 (43%)
Neuroendocrine 15 (19%)
Colorectal cancer 7 (8.9%)
GIST 3 (3.8%)
Breast cancer 2 (2.5%)
Cholangiocarcinoma 2 (2.5%)
Other 5 (6.3%)
1Oken MM, Creech RH, Tormey DC, Horton J, Davis TE,
McFadden ET, et al. Toxicity and response criteria of the Eastern
Cooperative Oncology Group. Am J Clin Oncol 1982;5(6):64955.
2Includes 2 patients with peripheral/metastatic cholangiocarcinoma.
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(ECOG) performance status (ECOG status 0 or
1)[14]. The most common histology was HCC
(57%). A significant proportion of patients (43%),
however, were treated for liver-dominant metastatic
disease. Neuroendocrine tumors (19%), including
carcinoids, were the most common metastatic etiology.
Procedural details and complications are shown in
Tables II and III, respectively. Most procedures were
chemoembolizations (84%). The remaining proce-
dures were performed using ethiodol/PVA bland
embolization (TAE). One procedure could not be
successfully completed and no embolization was
performed. This procedure was not included in
comparative analysis. With both TAE and TACE,
the histologies were almost equally distributed be-
tween HCC and metastatic disease. The median
length of stay for all procedures was four days (Table
II).
The overall procedural complication rate was 13%
(Table III). Organ failure occurred uncommonly, with
a 5% incidence of renal failure and a 6% incidence of
hepatic failure. Of the seven patients with hepatic
failure, two had mild liver dysfunction that resolved
spontaneously and four had severe acute liver dys-
function with hepatorenal syndrome. The remaining
patient had multi-organ system failure secondary to
respiratory insufficiency/respiratory distress which
was not directly related to embolization. Of the six
cases of renal failure, four were secondary to severe
hepatic dysfunction/hepatorenal syndrome and one
was secondary to multi-organ system failure. The
remaining case had a mild increase in BUN/creatinine
which resolved without intervention. Seven [7] deaths
occurred within one month of treatment for an overall
mortality rate of 5.9%. Five of these deaths occurred
during the initial hospital admission, three resulting
from severe liver dysfunction after embolization, and
two from cardiorespiratory events related to under-
lying comorbidity. An additional patient was admitted
two weeks after discharge with gastric perforation
related to non-target embolization of the right gastric
artery, and eventually died of septic complications. In
all, five of the seven deaths were directly related to the
embolization procedure.
Response to TAE/TACE
Table IV shows lesion response collectively for all
lesions and stratified by type of embolization, vascu-
larity and initial lesion size. There was a significant
overall decrease in lesion size following TAE/TACE
with a mean absolute decrease of 6.9 mm91.4 mm
Table II. Procedural details (n119 procedures; TACE, transar-
terial chemoembolization; TAE, transarterial bland embolization;
HCC, hepatocellular carcinoma).
Results/Frequency (%)
Type of embolization
TACE 100 (84.0)
HCC 50
Non-HCC 50
TAE 18 (15.1)
HCC 10
Non-HCC 8
Unsuccessful 1 (0.8)
Length of stay, median (range) Four days (115)
Table III. Procedural complications (n119 procedures).
Complication Frequency (%)
Any complication (morbidity)1 15 (13%)
Bleeding 2 (2%)
Hematoma 3 (3%)
Renal failure 6 (5%)
Hepatic failure 7 (6%)
Infection 3 (3%)
Unable to treat1 2 (2%)
30-day all-cause mortality 7 (5.9%)
1Unable to treat non-included in overall complication rate.
Table IV. Individual lesion response (n121 assessable lesions in
56 patients; TACE, transarterial chemoembolization; TAE, trans-
arterial bland embolization).
Decrease in
maximaldiameter
(mean9SE) p-Value
All lesions (n121)
Absolute 6.9391.36 mm pB0.001
Relative 10.391.9%
Type of embolization
TACE (n98)
Absolute 8.2991.57 mm pB0.001
Relative 12.292.2%
TAE (n23)
Absolute 1.1792.31 mm P0.62
Relative 2.293.3%
p for
comparison
0.04
Vascularity1
Hypervascular (n32)
Absolute 4.5693.19 mm p0.16
Relative 6.394.3%
Hypovascular (n57)
Absolute 7.0791.81 mm pB0.001
Relative 12.492.8%
p for
comparison
0.34
Initial Lesion Size2
B6.5 cm (n60)
Relative
12.193.0% pB0.001
]6.5 cm (n61)
Relative
8.692.6% p0.001
p for
comparison
0.38
1Includes 89 lesions for which vascularity was assessable. The
vascularity of remaining lesions could not be assessed, e.g., due to
non-contrast scans.
2Only relative changes compared.
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and relative decrease of 10.3%91.9% (pB0.001).
This change was significantly greater with TACE
compared to TAE (comparison pB0.04), with no
significant decrease in lesion size noted in the TAE
subgroup (1.292.3 mm, p0.62).
Stratified by vascularity, there was a significant
decrease in size after the treatment of hypovascular
lesions (7.191.8 mm, pB0.001) with a smaller, non-
significant decrease in the hypervascular group (4.69
3.2, p0.16). On statistical comparison of the two
groups, however, the response did not differ signifi-
cantly by lesion vascularity (p0.34). With respect to
pre-treatment lesion size, a significant relative de-
crease was noted for both small and large lesions
(12.193.0% and 8.692.6%, respectively, pB0.01)
with no significant difference in response between the
two groups (Table IV).
Table V shows lesion response stratified by histology.
A significant treatment response was observed in both
HCC and metastatic lesions, with no significant
difference between the two groups (p0.67). The
response with neuroendocrine tumors, including car-
cinoids, was slightly better than non-neuroendocrine
lesions (9.9 mm/2.1 mm, pB0.001, vs. 5.4 mm9
1.8 mm, p0.003). However, there is no statistically
significant difference between the two groups (com-
parison p0.13). Examination of carcinoid lesions
alone reveals a significantly better response in this
subgroup compared to all other lesions (15.4 mm9
3.2 mm vs. 5.5 mm91.5 mm, comparison p0.009).
Table VI shows the procedural response rates by
RECIST criteria for the entire population and after
stratifying by procedure type and histology. There
were no CRs after embolization. The overall radio-
graphic PR rate was 12.3%, with a progression rate of
4.5% (Table VI). Most procedures resulted in SD
(82.2%). There was no statistically significant differ-
ence in response comparing TAE to TACE (p0.16).
However, all of the PRs occurred following TACE
with no responses in the TAE group. The PD rate was
also lower in the TACE group (4.9% vs. 8.3%).
Stratified by histology, there was no difference in
response comparing HCC to metastatic disease (p
0.98). Of the five responses in the metastatic sub-
group, three occurred in patients with neuroendocrine
tumors, one in a patient with colorectal metastases,
and one in metastatic breast cancer with PR rates of
15.8% (one of 19), 8.3% (one of 12) and 33.3% (one
of three) in these groups, respectively. The radio-
graphic response rates were slightly but non-signifi-
cantly better in metastatic neuroendocrine tumors
compared to all other histologies combined (PR
15.8% vs 11.1%, respectively, p0.26). Similarly,
there was a trend toward improved radiologic re-
sponse in carcinoid tumors compared to non-carci-
noid disease (PR 37.5% vs 9.2%, p0.10). The
Table V. Individual lesion response stratified by histology (n121
assessable lesions in 56 patients; HCC, hepatocellular carcinoma).
Histology
Decrease in maximal
diameter (mean9SE) p-Value
HCC (n45)
Absolute 6.2892.00 mm p0.003
Relative 9.293.1%
Non-HCC (n76)
Absolute 7.3291.83 mm pB0.001
Relative 11.092.5%
p for
comparison0.67
Neuroendocrine (n41)
Absolute 9.992.1 mm pB0.001
Relative 14.693.3%
Non-neuroendocrine (n80)
Absolute 5.491.8 mm p0.003
Relative 8.192.4%
p for
comparison0.13
Carcinoid (n18)
Absolute 15.493.22 mm pB0.001
Relative 22.795.7%
Non-carcinoid (n103)
Absolute 5.4691.45 mm pB0.001
Relative 8.292.0%
p for
comparison0.009
Table VI. Procedural response rates (n73 procedures with assessable response; TACE, transarterial chemoembolization; TAE, transarte-
rial bland embolization, HCC, hepatocellular carcinoma).
Partial response Stable disease Progressive disease p-Value
All procedures (n73) 9 (12.3%) 60 (82.2%) 4 (5.5%)
Procedure type1
TACE (n61) 9 (14.8%) 49 (80.3%) 3 (4.9%) 0.17
TAE (n12) 0 (0%) 11 (91.7%) 1 (8.3%)
Histology
HCC (n33) 4 (12.1%) 27 (81.8%) 2 (6.1%) 0.98
Metastatic (n40) 5 (12.5%) 33 (82.5%) 2 (5.0%)
Metastatic neuroendocrine (n19) 3 (15.8%) 16 (84.2%) 0 (0%) 0.26
All others (n54) 6 (11.1%) 44 (81.5%) 4 (7.4%)
Metastatic carcinoid (n8) 3 (37.5%) 5 (62.5%) 0 (0%) 0.10
All others (n65) 6 (9.2%) 55 (84.6%) 4 (6.2%)
1Does not include one procedure with failed embolization.
400 A. Artinyan et al.
comparison fails to reach significance likely due to a
lack of power given the small sample size in the
carcinoid group (n8).
In the case of procedures with no post-procedure
scans where a death occurred less than six months
from the time of treatment, categorization of this
group as PD did not change the relationships ob-
served above (data not shown). This indicates that,
although there is the potential for the introduction of
selection bias by patients who died prior to post-
procedure scanning, the bias does not appear to have
affected the above results.
The median survival (MS) for the entire sample
population was 8.7 months. The median survival for
patients who had an assessable radiologic response
was 17.6 months. Figure 1 shows the Kaplan-Meier
survival curves comparing patients with HCC and
metastatic disease. There is no significant difference
in survival between the two groups (MS 7.7 vs.
9.7 months, respectively, p0.42). The Kaplan-
Meier curves stratified by procedural response are
shown in Figure 2. As evident from the overlapping
curves, there is no significant survival advantage in
patients with a PR to an embolization procedure
compared to patients with SD or progression (MS
22.5 vs. 26.3 months, respectively, p0.93).
Discussion
TAE and TACE have been among the most com-
monly used regional modalities for the treatment of
unresectable hepatic malignancies [13]. However,
multi-institutional phase III studies demonstrating the
benefit of TAE and TACE are lacking and uniform
therapeutic indications and patient selection criteria
have yet to be established. As a result, it is unclear
which patients truly benefit from embolization ther-
apy. In addition, there is no consensus whether TACE
is better than TAE alone. In light of these uncertain-
ties, we performed an institutional review of TAE and
TACE in a consecutive series of patients with primary
and metastatic hepatic malignancies. The purpose of
the study was to provide an objective evaluation of the
results of TAE and TACE using consistent and
uniform criteria for response and to identify tumor,
patient, and procedure based predictive factors for
improved response. Using our findings in the context
of existing evidence, we also provide an algorithmic
approach for the use of TAE and TACE in unresect-
able hepatic malignancies.
In the current study, treatment response was
assessed in three ways: (1) change in size of individual
lesions; (2) procedural response based on RECIST
criteria; and (3) overall survival. Our results demon-
strated that both TAE and TACE were well tolerated
and performed safely. Our complication rate was 13%
with a procedural mortality of 5.9%. Both figures are
at the lower range of reported rates [1518]. Of note,
we did not include post-embolization syndrome as a
complication because an accurate estimate of its
incidence was not possible from retrospective chart
review.
With respect to treatment response, TAE and
TACE resulted in a measurable and statistically
significant decrease in the size of treated lesions.
The procedural response rate was 12% by RECIST
criteria and was independent of pre-treatment lesion
size and vascularity. Primary HCC and metastatic
disease responded similarly to treatment. Carcinoid
tumors had the largest relative reduction in lesion size
(23%) and the highest RECIST response rate (37%).
Radiologic response rates in the literature have ranged
between 16 and 61% [1,11,19]. The lower response
rate observed in our series may be secondary to a
number of factors. Although decreases in lesion size
occurred commonly after embolization, the change in
maximal diameter was often not large enough to be
captured by RECIST criteria. A clinically significant
decrease in tumor activity may still have been present
in such cases. It is now known that response to
therapy is often not reflected by changes in lesion
size and other lesion characteristics, such as necrosis,
may be equally critical in assessing treatment response
[2023].
Our data suggest that the addition of chemotherapy
may provide an advantage over bland embolization
Figure 1. Survival estimates stratified by histology.
Figure 2. Survival estimates stratified by response.
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alone. TACE was associated with a significantly
greater decrease in individual lesion size compared
to TAE. PRs were observed only after TACE, with no
partial responders following TAE, although there was
no significant difference on statistical comparison.
Interestingly, TACE has never been shown to be more
effective than TAE in a trial directly comparing these
treatments. However, only TACE has been shown to
provide a survival benefit over best supportive care in
prospective randomized studies [11,24].
The overall survival observed in our population was
less than 10 months and is indicative of the relatively
advanced stage of disease in our treatment population
(mean pre-treatment lesion size of 9 cm, 50% of
patients multiple lesions). None of the patients
underwent surgical resection or transplantation after
treatment. There was no significant difference in
survival comparing patients who had a radiologic
response after TAE/TACE to those with either stable
or PD. This finding is likely influenced by the small
sample size  specifically the small number of respon-
ders  which does not allow detection of a small
potential survival benefit. Additionally, it is possible
that the non-responders in this group benefited
similarly to responders, but the treatment benefit
was not captured by RECIST criteria.
Survival rates following TAE/TACE have varied
widely in the literature, with one and two-year figures
as high as 82 and 63%, respectively, in HCC [1,11].
Of the several single institution prospective trials, only
two have identified a survival advantage with TACE in
HCC, both using highly selected patient populations
and multiple, planned retreatments [11,24]. In the
setting of metastatic disease, significant response to
second-line TACE has been demonstrated in patients
with colorectal hepatic metastases [2529]. Addition-
ally, several retrospective series have demonstrated the
potential for prolonged survival in metastatic mela-
noma [3032], peripheral cholangiocarcinoma [33],
and metastatic breast cancer treated with TACE [34].
TAE and TACE have been particularly applicable in
metastatic neuroendocrine tumors, with response
rates ranging from 33 to 80% independent of specific
tumor type [35].
Our study has a number of limitations. First,
because response was assessed only in patients who
had both pre-procedure as well as post-procedure
imaging, our findings are subject to some degree of
selection bias. We attempted to correct this selection
bias by recategorizing response as ‘‘progressive dis-
ease’’ in patients who had no post-procedure scan
and died within six months of treatment. Recategor-
ization in this manner did not significantly change
the reported response rates or comparisons. Addi-
tionally, while we were able to identify the histology
of the malignancy being treated from the medical
record, information about the underlying primary
disease and the extent of liver dysfunction could not
be consistently assessed from the medical record.
Given the results of our series and evidence from
the existing literature, we recommend the following
algorithmic approach to the selection and treatment of
patients via transcatheter embolization. For HCC
patients who are not eligible for surgery or transplant,
the extent of the tumor burden should be assessed
with triple-phase contrast CT or gadolinium-en-
hanced MRI. Additional studies should be used to
confirm liver-only or liver-dominant disease. Sympto-
matic patients with pain referable to the mass may
benefit from a reduction in tumor volume. Asympto-
matic patients with liver-dominant disease, even in the
presence of extra-hepatic disease, also warrant con-
sideration for treatment. In such cases, treatment
should be undertaken only if the extent of extrahepa-
tic disease is small. Ablative therapies, such as radio-
frequency ablation can be considered for lesions B5
cm. For larger lesions, TAE or TACE is the next best
option. Chemoembolization appears preferable to
bland embolization, although the choice of che-
motherapeutic agent is debatable. Cisplatin, doxor-
ubicin, and mitomycin with emulsification in lipiodol
is our cocktail of choice [12].
In the case of metastatic hepatic disease, the
primary therapy should be surgery and/or systemic
chemotherapy. When conventional strategies have
failed or are known to be ineffective, such as with
neuroendocrine tumors, embolization therapy may be
considered. With neuroendocrine tumors, TACE is
generally effective and should be employed. The
preference of TACE over TAE in this setting is based
on our observations as well as other series demon-
strating response to chemoembolization [3638]. In
addition, a recent study demonstrated a trend toward
improved survival with TACE vs. TAE with neuroen-
docrine metastases [39]. With other histologies, in the
absence of clinical trials, TACE should be considered
with the same regimen listed above. In the setting of
colorectal hepatic metastases, current first-line che-
motherapeutic agents are very effective. Second and
third-line regimens incorporating biologic targeted
therapies have also been shown to produce response.
TACE remains an alternative when these measures
have failed. TAE should also be considered in patients
who are unfit for chemotherapy secondary to medical
comorbidities. In addition, with multiple lesions of
varying size, combined RFA and TACE can be used
to treat the same or opposite lobes.
With respect to patient selection, treatment should
be avoided in patients with decompensated liver
disease (Child’s C cirrhosis). Main portal vein throm-
bosis is a contraindication to arterial embolization.
Based on our findings, large lesion size should not
preclude treatment, as response was independent of
size in our study. Additionally, hypovascularity should
not preclude treatment, as a significant response to
TACE was demonstrated in patients with both
hypervascular and hypovascular lesions.
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In conclusion, our experience demonstrates that
arterial embolization procedures can be performed
safely with low procedural morbidity and mortality.
Using uniform criteria, we show a modest but
significant PR to embolization, with significant
reductions in lesion size. Response was consistent
regardless of size or vascularity of lesions. Our data
suggest a greater benefit with TACE compared to
TAE. This finding requires confirmation in further
trials. The objective tumor response achieved with
TACE and TAE merits their continued use in
patients with advanced primary and metastatic liver
malignancies.
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